This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Global Anticoagulants Industry

Anticoagulant Therapy in IPF: Reduces Mortality Risk II-5

Anticoagulants to Lose UA/AMI Markets to Antiplatelets II-5

An Opportunity to Grow Further II-5

Warfarin & Heparins: The Former Market Leaders II-5

Generics Drugs Prevail in the Anticoagulant Market II-6

Concern Over Underutilization of Warfarin II-6

Novel Oral Anticoagulants to Turbo-Charge Market Growth II-7

Hurdles Exist for New Oral Agents II-7

The Merits and Demerits of New Age Anticoagulants II-7

Lack of Adequate Trials Mar Pediatric Anticoagulants Market II-8

Improved Anticoagulant Agents for Children Group II-8

Growing Demand for Self-Testing II-8

LMWHs Ease Outpatient Management II-8

Novel Heparins Enhance Market Potential II-9

A Focus on Failed or Withdrawn Agents in Recent Past II-9

Idraparinux and Idrabiotaparinux Sodium - Sanofi's

Discontinued Agents II-9

Lack of Statistical Significance Leads to Culmination of

Tecarfarin's Development II-10

Sofigatran - A Failed Agent from Mitsubishi Tanabe Pharma II-10



Traditional Oral Anticoagulants II-11

Warfarin II-11

Advantages and Alternatives II-11

Side Effects II-11

Limitations II-12

Coumadin - The Branded Warfarin II-12

Novel Oral Anticoagulants II-12

Dabigatran Etexilate (Pradaxa) II-12

Table 1: Pradaxa and Warfarin - A Comparative Study II-13

Approved Indications for Pradaxa in Select Regions II-13

Rivaroxaban (Xarelto) II-13

Approved Indications for Xarelto in Select Regions II-14

Xarelto Patent Expiration in Various Regions II-14

Apixaban (Eliquis) II-15

Betrixaban II-15

Comparison of Select Approved and Pipeline Anticoagulant

Agents in a Nutshell II-15

Market Dynamics II-16

New Oral Drugs More Efficacious In Reducing Stroke II-16

New Generation Anticoagulants Enter the Market, Warfarin

Comes Under Pressure II-16

Oral Anticoagulants Market to Witness Intense Competition II-16

Pradaxa- A High Potential Replacement to Warfarin II-17

Packaging May Hurt Pradaxa's Prospects II-17

New Oral Drugs in Various Indications II-17

Emerging Targets in the Anticoagulation Space II-18

Daiichi Sankyo Upbeat on Prospects of Edoxaban II-18

ELIQUIS' FDA Approval Faces Further Delays II-19

2 of 15

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $162.60 0.00%
YHOO $27.97 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs